Wu JD, Li JX, Liu J, Wang HM, et al. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged >/=18 years: a randomised, double-blind, phase 2b trial. Lancet Infect Dis 2023 May 19:S1473-3099(23)00199.
PMID: 37216958